Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 5/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 6/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3681768 | 0.94 | PRKD1 (0.41) | PRKD1TAS1R3TAS1R1TMPRSS15MMEL1 | |
| SCHEMBL13409967 | 0.94 | PRKD1 (0.43) | PRKD1TAS1R3TAS1R1MMEL1F10 | |
| SCHEMBL3681771 | 0.87 | PRKD1 (0.41) | PRKD1TAS1R3TAS1R1NPSR1 | |
| SCHEMBL13443949 | 0.80 | HDAC8 (0.49) | MMEL1MMESUCNR1 | |
| SCHEMBL4787690 | 0.72 | RAF1 (0.36) | PRKD1 | |
| Trifluoroacetic Acid SCHEMBL3679506 | 0.72 | MMP2 (0.44) | — | |
| SCHEMBL14069885 | 0.72 | NPC1 (0.51) | MMEL1NPSR1 | |
| SCHEMBL13444645 | 0.71 | CTRB1 (0.46) | TAS1R3TAS1R1PIN1 | |
| SCHEMBL13409957 | 0.71 | ACACB (0.47) | TAS1R3TAS1R1PIN1 | |
| Trifluoroacetic Acid SCHEMBL3690939 | 0.69 | PPARG (0.53) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | PRKD1 1975/4885TAS1R3 4074/4885TAS1R1 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.